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Abstract
BACKGROUND: Osteoarthritis (OA) is a degenerative joint disease in one or more joints characterized by changes 
in pathological structures such as cartilage, hypertrophy, and remodeling of the subchondral bone and secondary 
inflammation of the synovium membrane, causing changes in joint components such as cells, matrices, and 
molecular production. At the molecular level, an imbalance between catabolic and anabolic activities in joint cartilage 
results in OA. Nuclear factor kappa beta (NFκβ) is a cytokine that plays an important role in the signaling pathway 
of the pathogenesis of OA in causing an inflammatory reaction, whereas interleukin (IL)-10 is an anti-inflammatory 
cytokine that is involved in the pathogenesis of OA.
AIM: This study aims to prove the influence before and after administration mesenchymal stem cells from Wharton’s 
jelly on the serum NFκβ and IL-10 levels in OA rat models.
MATERIALS AND METHODS: This research is an experimental study with the design of post-test-only control group 
design. The sample consisted of 16 OA rats as a control group and 16 OA rats treated with MSC-WJ as a treatment 
group. OA induction is done by injection of monosodium iodoacetate (MIA) into the intra-articular right knee. Giving 
MSC-WJ is done in the 3rd week after MIA induction. The serum NFκβ and IL-10 levels were measured after 3 weeks 
treated with MSC-WJ using the ELISA method. The statistical test used is an independent t-test. p < 0.05 was said 
to be statistically significant.
RESULTS: From the research results obtained, serum levels of knee OA of rat knee OA treated with mesenchymal 
stem cell Wharton jelly are lower than serum NFκβ levels of knee OA of the rat that is not treated, but the difference 
in levels of NFκβ is not significant (p > 0.05). The serum IL-10 level of rat OA of knee treated with mesenchymal stem 
cell Wharton jelly was higher than the serum IL-10 level of rat OA of the knee that was not treated, difference in levels 
of IL-10, is significant (p < 0.05).
CONCLUSION: This study concluded that MSC-WJ significantly decreased the serum NFκβ levels of OA rats and 
not significantly increased the serum IL-10 levels of OA rats.
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Introduction
Osteoarthritis (OA) is a degenerative joint 
disease in one or more joints characterized by changes 
in pathological structures such as cartilage, hypertrophy, 
and remodeling of the subchondral bone and secondary 
inflammation of the synovium membrane [1]. OA is no 
longer considered a degenerative disease, but age 
remains one of the risk factors. As we get older, the 
possibility of OA increases. OA is the most common 
arthritis in the world. OA is a cause of disability in 
millions of patients, including about 60–70% of people 
over the age of 60 years. Overtime, the challenges in 
the right treatment for OA will be even greater because 
of the increasing population of the elderly population; 
therefore, in handling the problem of OA, a variety of 
therapies are needed [2].
At the molecular level, an imbalance between 
catabolic and anabolic activity in joint cartilage results in 
OA. The main catabolic factors are played by interleukin 
(IL)-1 and tumor necrosis factor-α (TNF-α) stimulated 
by nuclear factor kappa beta (NFκβ) which contribute to 
the inflammatory process in OA. The anabolic factors 
are played by IL-4, IL-10, and transforming growth 
factor-beta. IL-10 is a pro-inflammatory cytokine that 
has a positive effect on the inflammatory reaction of 
OA. A study conducted by Driessler, in 2004, showed 
that IL-10 can inhibit NFκβ through inhibition of p65 
so that the inflammatory process can be suppressed 
by increasing IL-10 and preventing the degradation 
process more quickly. Degradation and synthesis of 
normal cartilage matrix molecules are controlled by 
chondrocytes constantly [3].
Until now, therapies that can cure OA with 
satisfactory results have not been found. Management 
of OA is primarily intended to relieve pain, improve 
motion and joint function [4]. Pharmacological therapy 
in OA has many undesirable effects resulting from 
long-term use of drugs, such as the use of long-term 
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nonsteroidal anti-inflammatory drugs, resulting in peptic 
ulcers and impaired kidney function. For patients who 
are not responsive to pharmacological therapy, a total 
knee replacement surgery will be performed. The effort 
to maintain the joints is done in several ways, namely, 
injection with hyaluronic acid, platelet-rich plasma, and 
cell-based therapy such as mesenchymal stem cell.
This research uses experimental animals, 
male white rats. Rats were injected intra-articular with 
monosodium iodoacetate (MIA) into the rat knee joint. 
The development of joint pathology in this way can be 
controlled with the injected monoiodoacetate dose, thus 
providing a useful model system for evaluating potential 
OA modulators [6].
Based on the background description above, 
where the use of stem cells can be used as an alternative 
for OA therapy, the authors are interested in conducting 
in vivo research related to the effect of mesenchymal 
stem cells from Wharton’s jelly on decreasing NFκβ and 
increasing IL-10 concentrations in rat serum OA of the 
knee.
Materials and Methods
Animal and experimental design
Male white rats (Rattus norvegicus) with 
a weight ranging from 200 to 250 g as experimental 
animals placed in clean, disinfected, and pathogen-free 
cages and given standard food in the form of pellets and 
drinking in ad libitum. Trial animals adapted first for 1 
week before treatment. Induction of OA conducted with 
300 µg intra-articular injection of MIA (Sigma-Aldrich, 
USA) in 50 µl of saline solution (0.9% NaCl) sterile 
[7] singly into the right knee joint rats anesthetized 
by intraperitoneal injection of xylazine 10 mg/kg and 
ketamine 20 mg/kg uses insulin syringe with a needle 
27G [8]. Thirty-two OA male white rats (3 weeks after 
MIA induction) were divided into two treatment groups 
(n = 16): Control group and MSC-WJ group. MSC-WJ 
group is given 50 µl MSC-WJ with a dose of 1 × 106 
cells into the right knee joint and a control group given 
50 µl complete medium after anesthetized. Rats were 
sacrificed after 3 weeks of treatment. Serum and knee 
joint were taken and then analyzed.
Analysis of flow cytometry
Mesenchymal stem cell Wharton jelly was 
obtained from the Indonesian Medical Education 
and Research Institute (IMERI), Faculty of Medicine, 
University of Indonesia. Based on the analysis of flow 
cytometry, MSC-WJ used for this therapy had CD73-
APC cell surface expression 99.8%, CD105-PerCP-
Cys5.5 95%, and CD90-FITC 99.9%. Photocell was 
taken use Nikon Ti-S microscope, scale bar: 500 μm 
(Figure 1).
Measurement of serum NFκβ and IL-10 by 
ELISA
Blood was taken from sinus periorbital and 
centrifuged at 3000 rpm for 15 min. The collected 
serum was stored at −80°C until measurement. Serum 
NFκβ and IL-10 levels were measured by an ELISA kit 
(Bioassay Technology Laboratory, China). All samples 
are measured in duplicate.
Examination of levels NFκβ (work protocol 
based on rat NFκβ ELISA kit)
Prepare all reagents, standard solutions and 
samples as instructed. Bring all reagents to room 
temperature before use. The assay is performed at 
room temperature. Determine the number of strips 
required for the assay. Insert the strips in the framers for 
use. The unused strips should be stored at 2–8°C. Add 
50 μL standard well. Add 40 μL sample to sample wells 
and then add 10 μL anti-NFκβ antibody to sample wells, 
then add 50 μL streptavidin-HRP to sample wells and 
standard wells (not blank control well). Mix well. Cover 
the plate with a shaker. Incubate 60 min at 37°C. 
Remove the sealer and wash the plate 5 times with 
wash buffer. Soak wells with at least 0.35 ml wash 
buffer for 30 s to minute for each wash. For automated 
washing, aspirate all wells and wash 5 times with wash 
buffer, overfilling wells with wash buffer. Blot the plate 
onto paper towels or other absorbent material. Add 
50 μL substrate solution A to each well and then add 
50 μL substrate solution B to each well. Incubate plate 
covered with a new sealer for 10 min at 37°C in the 
Figure 1: Data on characteristics of mesenchymal stem cells Wharton 
jelly; (a) Cells MSC-WJ reach confluence. Scale bar: 500 μM. 
Photographs of cells taken using a Nikon Ti-S microscope; (b) Data 
flow cytometry. Forward scatter plot and side scatter plot. Population 
gated events (P1): 20,000; (c) Cell surface markers expression: 
CD73-APC 99.8% and CD105-PerCP-Cy5.5 95%; (d) Cell surface 
markers expression: CD90-FITC 99.9% and Lin (−)-PE 0.4%
a b
c d
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dark. Add 50 μL stop solution to each well; the blue 
color will change into yellow immediately. Determine 
the optical density (OD) value of each well immediately 
using a microplate reader set a 450 nm within 30 min 
after adding the stop solution.
Examination of IL-10 levels (work protocol 
based on rat IL-10 ELISA kit)
Prepare all reagents, standard solutions and 
samples as instructed. Bring all reagents to room 
temperature before use. The assay is performed at 
room temperature. Determine the number of strips 
required for the assay. Insert the strips in the framers 
for use. The unused strips should be stored at 2–8°C. 
Add 50 μL standard well. Add 40 μL sample to sample 
wells and then add 10 μL anti-IL-10 antibody to sample 
wells, then add 50 μL streptavidin-HRP to sample wells 
and standard wells (not blank control well). Mix well. 
Cover the plate with a shaker. Incubate 60 min at 37°C. 
Remove the sealer and wash the plate 5 times with 
wash buffer. Soak wells with at least 0.35 ml wash 
buffer for 30 s to minute for each wash. For automated 
washing, aspirate all wells and wash 5 times with wash 
buffer, overfilling wells with wash buffer. Blot the plate 
onto paper towels or other absorbent material. Add 
50 μL substrate solution A to each well and then add 
50 μL substrate solution B to each well. Incubate plate 
covered with a new sealer for 10 min at 37°C in the 
dark. Add 50 μL stop solution to each well; the blue 
color will change into yellow immediately. Determine the 
OD value of each well immediately using a microplate 
reader set a 450 nm within 30 min after adding the stop 
solution.
Research ethics
This study was already passed the ethics 
clearance and has been approved by the Ethics 
Committee of the Faculty of Medicine, Andalas 
University, Padang, with registration number: 192/KEP/
FK/2019.
Statistical analysis
Data are presented in mean and elementary 
forms. The statistical analysis used is SPSS 18.0. The 
statistical test used is an independent t-test. p < 0.05 
was said to be statistically significant.
Results
OA rats were divided into two groups, namely, 
the OA group and the group treated with MSC-WJ. 
Examination of the levels of NFκβ and IL-10 was carried 
out in the serum of rats by ELISA.
ELISA examination
The blood obtained from the centrifuged 
animal is then obtained serum. Serum before analysis 
was stored in a refrigerator temperature of −80°C. The 
serum obtained was determined by NFκβ and IL-10 
levels, carried out in the Biomedical Laboratory, Faculty 
of Medicine, Andalas University.
The results of the measurement of NFκβ and 
IL-10 levels were carried out in normal rat, and the 
mean levels of NFκβ and IL-10 were 0.58 ng/mL and 
6.05 pg/mL. Based on the results of the normality test, 
the data show that the two research variables, namely, 
NFκβ and IL-10 are normally distributed (p > 0.05). 
Thus, the parametric test (independent t-test) can then 
be carried out.
Effect of MSC-WJ on NFκβ levels in serum 
of OA rats
The results of the measurement of NFκβ levels 
by ELISA method showed that the serum NFκβ levels 
of OA rats treated with MSC-WJ were lower than those 
not treated which are shown in Figure 2.
Figure 2: Boxplot graph of rat serum nuclear factor kappa beta 
levels
The difference in NFκβ levels between the 
serum of rats treated with MSC-WJ and not treated 
bivariate test is shown in Table 1.
Table 1 and Figure 3 show that there are 
differences in levels of NFκβ based on treatment. 
Decreased levels of NFκβ in the group treated with 
MSC-WJ from the control group. Statistically, the 
differences were not significant (p>0.05).
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Effect of MSC-WJ on IL-10 levels in serum 
of OA rats
The results of the measurement of IL-10 levels 
by ELISA method showed that the serum IL-10 levels of 
OA rats treated with MSC-WJ were higher than those 
not treated with bivariate tests which are shown in 
Figure 4.
 
Figure 3: Histogram of rat serum nuclear factor kappa beta levels  
 
The difference in IL-10 levels between the serum of rats 
treated with MSC-WJ and not treated bivariate test is 
shown in Table 2.
Figure 4: Effect of MSC-WJ on IL-10 levels in serum of OA rats
Table 2 and Figure 5 show that there are differences in 
levels of IL-10 based on treatment. Increased levels of 
IL-10 in the group treated with MSC-WJ from the control 
group. Statistically, the differences were significant 
(p < 0.05).
Discussion
Formation of OA in rat
The formation of an OA mouse model in this 
study refers to the method used by Janusz et al., van 
Buul et al., and Javanmard et al. [6], [7], [8]. The dosage 
of MIA by following that used by van Buul et al., which is 
300 μg in a volume of 50 μL MIA is given intra-articularly. 
MIA is an inhibitor of glyceraldehyde-3-phosphate 
 
Figure 5: Histogram of rat serum interleukin-10 levels  
 
dehydrogenase which results in reduced glycolysis 
and causes changes in articular cartilage associated 
with histological and morphological features of OA by 
inhibiting the integration of subchondral structures and 
inducing chondrocyte cell death. The OA model induced 
by MIA is regularly used to measure behavior pain and 
drug therapy to overcome pain in animals. This model 
might be more stressful the efficacy of drugs than 
other pain models used to test OA drugs. Thing this is 
commonly used in rats and rat [9]. Surgically induced 
OA models may be more clinically relevant than model 
ones chemically induced related to the pathophysiology 
of OA. However, there are some disadvantages 
surgery-induced OA models, including the need for 
surgical manipulation for inducing OA and difficulty in 
reaching the severity of arthritis which can reproduce. 
Therefore, the OIA model that is used by MIA is used 
and confirmed reproducibility grade and stage of OA 
in rat [10]. Furthermore, MIA causes the development 
of recurrent synovial hyperplasia and infiltration of 
inflammatory cells, destroys articular cartilage, and 
induces bone loss and chondral deformation. MIA 
injection into the rat knee joint is considered a suitable 
Table 1: Mean differences in NFκβ levels by group
Group NFκβ levels (ng/mL) Mean±SD p value
OA 0.658±0.06
OA+MSC-WJ 0.647±0.04 0.53
Table 2: Mean differences in IL-10 levels by group
Group IL-10 levels (pg/mL) Mean±SD p value
OA 7.604±0.06
OA+MSC-WJ 16.144±0.04 0.00
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model and resembles the phenomenon observed in 
human OA [11].
Research by Matsumoto et al. [10] has also 
researched OA models on a rat. Sixty female rats 
were 10 weeks old (NIH-Whn NIHRNU-M; Taconic, 
Germantown, NY) which are used. The animal was 
given anesthetic 3% isoflurane and O2 gas (1.5 L/min) 
through inhalation mask OA-like arthritis induced by 
a single injection intrajoint MIA (Aldrich Chemical, 
Milwaukee, WI) (0.3 mg/150 mg body weight) into both 
rat knee joints. A chronic OA model with progressive 
manifestations was found 2 weeks after MIA injection 
which was compared with subacute OA models which 
manifested 1 week after MIA injection. MIA injection in 
the rat’s knee shows an increase in activity enzymes 
collagenase and gelatinase. In a study by Janusz et al. 
found increased levels of MMP and aggrecanase as 
well as proteoglycans, starting 7th day post-MIA injection 
until the 21st day and the administration of anti-MMP 
from day 7 can significantly inhibit cartilage damage [6].
The results showed that the induction of MIA in 
rat with a single dose of 300 μg after 3 weeks showed 
depletion of cartilage thickness. The results of this 
study are also the same as those conducted by Janusz 
et al. [6] concerning the effect of MIA on rat cartilage, 
where his research also occurred depletion of cartilage 
after MIA induction. This depletion of cartilage results 
from the loss of proteoglycans that build the matrix. 
Besides, the results of this study also showed a reaction 
in the form of proliferation of reactive chondroblast 
cells in rat induced by MIA so that a higher density of 
chondrocyte cells was found in the cartilage of OA rat 
compared to normal rat [12].
NFκβ
The NF-κβ molecules are a family of 
ubiquitously expressed transcription factors involved 
in immunity, stress responses, inflammatory diseases, 
cell proliferation, and cell death. The OA chondrocytes 
express a variety of NF-κβ-mediated catabolic 
cytokines and chemokines, such as TNF-α, IL-1, IL-6, 
receptor activator of NF-κβ (RANK) RANK ligand 
(RANKL), and IL-8 that increase the production of 
MMPs, decrease collagen and proteoglycan synthesis, 
and act in a positive feedback loop to augment NF-κβ 
activation.
In articular joint, the NF-κβ pathway is activated 
in chondrocytes and synoviocytes on stimulation by 
mechanical stress or cytokines (TNF-α and IL-1). 
Subsequently, the activated joint cells produce 
several MMPs, ADAMPTS, apoptotic molecules 
(cyclooxygenase 2 [COX2], nitric oxide [NO], and 
prostaglandin E2 [PGE2]), chemokines (IL-8), and 
cytokines (TNF-α, IL-1, and IL-6) which induce cartilage 
destruction and synovium membrane inflammation 
(synovitis). In addition, the cytokines TNF-α, IL-1, and 
IL-6 secreted by chondrocytes and synoviocytes activate 
osteoblasts to produce the RANKL cytokine which 
induces osteoclast-mediated bone resorption [13].
The activation of stress- and inflammation-
induced signaling and transcriptional and post-
transcriptional events results in release of the 
chondrocytes from growth arrest, imbalanced 
homeostasis, and chondrocyte activation with aberrant 
expression of inflammation-related genes, including NO 
synthase-2, COX2, and catabolic genes such as MMP-
1, 3, and 13 and ADAMTS-4 and 5 [5]. The signaling 
kinases activated by mechanical and inflammatory 
stimuli include the stress- and mitogen-activated ERK, 
p38, and JNK, which coordinately activate AP-1, ETS, 
Runx2, and C/EBP transcription factors, and IKKα and 
IKKβ, which activate, respectively, non-canonical (RelA/
p52) and canonical NF-κB (p65/p50) pathways [14].
In addition, the OA chondrocytes express 
a variety of NFκβ-mediated catabolic cytokines and 
chemokines, such as TNF-α, IL-1, IL-6, receptor 
activator of NFκβ, and IL-8 that increase the production of 
MMPs, decrease collagen and proteoglycan synthesis, 
and act in a positive feedback loop to augment NFκβ 
activation. Finally, the NFκβ molecules enhance the 
articular damage through induction of NO, COX2, NO 
synthase, and PGE2, which promote the synthesis of 
catabolic factors, cartilage inflammation, and apoptosis 
of OA chondrocytes [15].
From the results  of the t-test independent 
statistical analysis using SPSS version 18 software 
obtained significance value 0.531>0.05. This shows 
that there is no significant difference in the level of NFκβ 
between the OA rat groups that are not treated with 
OA rat treated by MSC-WJ. This is because NFκβ is a 
regulatory cytokine that functions to regulate the process 
of transcription of genes that play a role in inflammatory 
reactions. NFκβ is a transcription factor in mammals that 
control many important genes in the process of immunity 
and inflammation. NFκβ is found in all cell types involved 
in cellular responses to stimuli such as stress, cytokines, 
chemokines, free radicals, and others [16].
From the research results obtained related 
to NFκβ levels, some previous research results are 
relevant to the results of this study. The results of Chen’s 
et al. study, stated that NFκβ plays an important role in 
the process of differentiation from periodontal ligament 
stem cells to differentiate into bone (osteogenic). NFκβ 
is involved in regulating the inflammatory process and 
plays a role in increasing the ability of stem cells in the 
treatment of bone diseases [17].
Several studies to date have shown that NFκβ 
signaling plays an important role in certain parts of the 
activity of osteoclasts, osteoblasts, and chondroblasts. 
Some of these functions appear to be important during 
embryonic development, such as the role of NFκB 1 and 
2 in osteoclastogenesis. NFκβ activation seems to play 
an important role in endochondral ossification to prevent 
cartilage damage in animal models of rheumatoid arthritis 
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and OA. In this case, there is an opportunity in the 
development of drugs to promote or inhibit the activation 
of NFκB to treat or prevent common bone diseases, but 
to date, no one has been in clinical trials [18].
Research conducted by Guercio et al., in 2012, 
the administration of MSC by intra-articular injection in 
dogs with OA models showed a significant improvement 
in humeroradial joint compared to controls. Cell therapy 
is very potential before the onset of injury to OA [19]. 
The opposite regarding NFκβ was obtained from 
Chang et al.’s study in 2013 which found an association 
between pro-inflammatory cytokines such as TNF-α and 
IL-17 stimulated by Ikβ kinase (IKK)-NFκβ with failure 
of the MSC differentiation process to osteogenic on the 
contrary, IKK-NFκβ inhibition can significantly increase 
the ability of MSC in the process of bone formation [20]. 
During the differentiation process of MSC, there will 
be an increase in NFKβ gene activity and expression. 
The strength of pF unit NFKβ gene expression (RELA) 
causes the differentiation process of MSC [21].
IL-10
From the results, MSC-WJ can increase serum 
IL-10 levels in OA rat model, of the independent t-test 
obtained a significance value of 0.00 < 0.05. This shows 
that there are significant differences in IL-10 levels 
between groups of OA mice that are not treated with OA 
mice treated by MSC-WJ. The results of this study are 
in line with the study conducted by Yang et al., in 2009, 
which states that the administration of MSC can increase 
IL-10 levels which can suppress the proliferation of 
suppressor T cells that play a role in the occurrence 
of inflammatory reactions [22]. Research conducted 
by Jang, in 2019, states that MSC administration in 
mice irritable bowel disease model with IL-10 knock out 
can reduce the production of reactive oxygen species 
(ROS) which are oxidative stress agents and increase 
the production of antioxidant agents. Inflammation and 
ROS are closely related to tissue damage [23]. From a 
study conducted by Maiti et al., in 2019, it was stated 
that concomitant administration of MSC and IL-10 
can significantly stimulate the activation of autophagy, 
mitophagy, and other cell survival markers and can 
reduce markers from cell death and neuroinflammation. 
The administration of MSC and IL-10 together is 
possible as an effective therapeutic strategy to prevent 
neuronal damage in traumatic brain injury mice [24]. 
Research conducted by Liu et al., in 2013, states that 
the administration of MSC can inhibit the maturation of 
dendritic cells which are agents of antigen-presenting 
cells which play an important role in triggering an 
immune reaction. MSC inhibits the maturation of 
dendritic cells through the secretion of IL-10. MSC can 
stimulate the release of IL-10 which is one of the anti-
inflammatory cytokines [25].
The results obtained from this study were also 
supported this research conducted by Choi et al., in 
2008, in vitro coculture MSC and IL-10 were able to 
secrete IL-10 in large quantities. Intra-articular injection 
of IL-10 and MSC can significantly reduce the severity of 
arthritis. IL-10 is a contributing factor as a neuroprotective 
in MSC transplants after ischemic stroke [26]. From 
the results of the immunological analysis, experiments 
showed that transplantation of MSC and IL-10 can 
significantly inhibit microglial activation and expression 
of pro-inflammatory cytokines. Overexpression of 
IL-10 can increase the neuroprotective effect after 
administration of MSC through the mechanism of anti-
inflammatory modulation and thus can prevent the 
occurrence of more extensive nerve damage during 
the onset of acute ischemia [27]. IL-10 is the main anti-
inflammatory cytokine in the immune system that it plays 
a role for stop the excessive inflammatory response 
through the inactivation of macrophages and T cells. 
These cytokines are local and systemic inflammatory 
mediators that the body can produce in large quantities, 
so they are easily detected in serum [28].
This study can explain the effect of 
mesenchymal stem cells Wharton jelly on OA model 
mice through the parameters of serum levels of NFκβ 
and IL-10. In general, MSC-WJ can reduce serum 
NFκβ levels and increase serum IL-10 levels which are 
pro-inflammatory cytokines in OA. Mesenchymal stem 
cells Wharton jelly can increase IL-10 levels, which, in 
turn, can improve the damage to synovial tissue in OA, 
because IL-10 is an anti-inflammatory cytokine that 
plays an important role in protecting the joint cartilage 
matrix. The results of this study can also be useful as a 
reference for the use of stem cells, especially MSC-WJ 
as a promising OA therapy in future.
Conclusion
Based on the results of research that has been 
done can be concluded as follows, the NFκβ serum 
levels of knee OA rat treated with mesenchymal stem 
cell Wharton jelly are lower than the NFκβ serum levels 
of knee OA of the knee that is not treated, but the 
difference in NFκβ levels is not significant. IL-10 serum 
levels of knee OA rat treated with mesenchymal stem 
cell Wharton jelly are higher than IL-10 serum levels of 
knee OA rat that is not treated, the difference in IL-10 
levels is significant.
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